ProfileGDS5678 / 1423034_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 95% 95% 95% 95% 92% 95% 95% 95% 95% 95% 94% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.4382195
GSM967853U87-EV human glioblastoma xenograft - Control 28.5612795
GSM967854U87-EV human glioblastoma xenograft - Control 38.4239195
GSM967855U87-EV human glioblastoma xenograft - Control 48.627395
GSM967856U87-EV human glioblastoma xenograft - Control 58.6457995
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.3184495
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.3866192
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.2537595
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.402695
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.4792495
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.3441895
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.4838595
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.2486294
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.559495